Vemurafenib + fotemustin clinically active in BRAF-refractory melanoma

Access to the full content of this site is available only to registered healthcare professionals. Register to read more
Takeaway
  • The combination of vemurafenib plus fotemustine has clinical activity and manageable toxicity in patients with BRAF-mutated metastatic melanoma who experienced systemic progression while receiving single-agent BRAF inhibitor therapy.
Study design
  • Phase 2 single-group study conducted at 2 ...